Loading...
Market
What will be the impact of Morphic acquisition on Eli Lilly's immunology pipeline by December 31, 2025?
2
Resolution / Starting Odds
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%
Official statements from Eli Lilly, industry analysis reports, or reliable financial news sources
Story
Eli Lilly to Acquire Morphic Holding for $3.2 Billion at $57 per Share
Jul 8, 2024, 11:31 AM
Eli Lilly has announced its agreement to acquire Waltham-based Morphic Holding for approximately $3.2 billion, or $57 per share in cash. The acquisition aims to bolster Eli Lilly's immunology pipeline, particularly focusing on Morphic's lead program, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD). This deal represents a significant premium, with Morphic's stock surging by 78% following the announcement. The acquisition is expected to enhance outcomes for patients with IBD and strengthen Eli Lilly's position in the biopharmaceutical market. Tim Springer, a Morphic founder, noted that Lilly's bid was unexpected.
View original story
Similar markets
Major success • 25%
Moderate success • 25%
Limited success • 25%
Failure • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Significant enhancement • 25%
Moderate enhancement • 25%
No change • 25%
Negative impact • 25%
Diabetes • 25%
Obesity • 25%
Heart Disease • 25%
Chronic Pain • 25%
Major acquisition by competitor • 25%
New drug development announced • 25%
Price reduction of existing drugs • 25%
No significant response • 25%
Yes • 50%
No • 50%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Other • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No increase or decrease • 25%
